Galenica posts strong net sales
This article was originally published in Scrip
Executive Summary
Galenica's first-half net profits grew by 52% to CHF105 million ($96 million) as the firm's pharmaceutical sales rose despite the deteriorating US dollar. Drug sales rose by 8% to CHF211 million following robust sales of iron products in its Vifor Pharma division.